BMEA

BMEA

USD

Biomea Fusion Inc. Common Stock

$2.610+0.140 (5.668%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$2.470

最高价

$2.650

最低价

$2.435

成交量

2.30M

公司基本面

市值

98.1M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.91M

交易所

NMS

货币

USD

52周价格范围

最低价 $1.291当前价 $2.610最高价 $13.07

相关新闻

GlobeNewswire

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus

查看更多
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Analyst Upgrades

Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7

Piper Sandler analyst Edward Tenthoff assumes Biomea Fusion with a Overweight rating and announces Price Target of $7.

查看更多
Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7
Analyst Upgrades

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion with a Buy and maintains $16 price target.

查看更多
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
GlobeNewswire

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the

查看更多
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia